- Top court's gene patent ruling could affect biotech crops
A recent Supreme Court ruling that prohibits patenting of human genes could have negative implications for agricultural biotechnology, a BIO official and other experts said. The decision could reduce patent protections for biotech crops by making the fundamental gene fair game for competitors, BIO Deputy General Counsel Hans Sauer said. The ruling also could make technology that involves promoters of unchanged genes effectively unpatentable, Sauer said. Capital Press Agriculture (Salem, Ore.) (6/19)        | Analyst brief: Axendia: Lowering the Cost of Healthcare from the Inside Out
Healthcare administrators are seeking ways to manage a mix of Clinical, Biomedical, Facilities, Engineering and Health IT assets. Learn how Healthcare Executives are leveraging an integrated Enterprise Asset Management solution to enhance patient care and improve clinical outcomes, reduce costs and ensure compliance. |
 | Health Care & Policy |  |  | | - Ambrx allies with Chinese firms to develop breast cancer drug
Ambrx agreed to collaborate with Chinese firms Zhejiang Medicine and WuXi PharmaTech in the development and marketing of the antibody drug conjugate ARX788 for treatment of HER2-positive breast cancer. Zhejiang will shoulder the development costs and will get the right to market the drug in China. WuXi will provide development and production services for the toxin, antibody and ADC. Pharmaceutical Business Review Online (6/20) - FDA seeks more safety data on Idenix's hep C drug
The FDA has asked Idenix Pharmaceuticals to submit additional safety data on its hepatitis C drug candidate IDX20963 before it can proceed with human clinical trials. "The company anticipates a delay in the initiation of the clinical program for IDX20963 while it responds to the FDA's comments," Idenix said. Idenix also halted development of two other hepatitis C drugs this year after a similar compound from Bristol-Myers Squibb was tied to heart risks. Reuters (6/20), Bloomberg (6/21) - FDA will release notification rule to curb drug shortages
Drugmakers will have to notify the FDA about interruptions or discontinuances in the manufacturing of life-saving treatments under a proposed rule, which the agency is set to publish. The rule would mandate early notification from makers of drugs considered life-sustaining, life-supporting or used in the treatment or prevention of debilitating diseases. Health Data Management (6/19) | Company & Financial News | | | | - GSK to invest in venture fund for orphan drug discovery
GlaxoSmithKline is investing $23.5 million in Kurma Biofund II, a venture capital fund that works with a network of research institutes in Europe and focuses on rare diseases. GSK invested earlier this year in Avalon Ventures to fund up to 10 drug discovery startup companies over the next three years. Reuters (6/20) - NIH funds effort to test potential of abandoned meds
Nine academic groups will receive $12.7 million from the NIH to test the potential of abandoned experimental treatments for diseases such as schizophrenia, Duchenne muscular dystrophy and Alzheimer's. Development of the drugs previously was ended over issues concerning efficacy, safety or market potential. Forbes (6/18) | Food & Agriculture | | | | - EU should adopt biotech crops, U.K. environment secretary says
U.K. Environment Secretary Owen Paterson urged the European Union to loosen restrictions on biotech crops to meet future food demand. Biotechnology can potentially "reduce fertilizer and chemical use, improve the efficiency of agricultural production and reduce post-harvest losses," Paterson said during a speech at Rothamsted Research in Harpenden, U.K. BBC (6/20), Bloomberg (6/20) | Industrial & Environmental | | | | | News from BIO | | | | - Secure document sharing services optimized for life science organizations
ShareVault, a leading provider of highly secure and controlled document sharing solutions and virtual data rooms (VDR), has aligned with BIO to provide companies with significant discounted pricing and complimentary extra features. ShareVault's VDR platform is optimized for life science companies of all sizes and flexibly priced so that even small biotech companies can afford and benefit from its technology. The ShareVault solution is intended for due diligence required during bio-pharma partnering, licensing, fundraising, M&A, clinical study management or other applications that require secure sharing of documents with third parties. Learn more and sign up for a free trial.
| SmartQuote | | | |  | People of mediocre ability sometimes achieve outstanding success because they don't know when to quit. Most men succeed because they are determined to."
--George Allen,
American football coach  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Thursday, June 20, 2013
- Wednesday, June 19, 2013
- Tuesday, June 18, 2013
- Monday, June 17, 2013
- Friday, June 14, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment